The Investigator Initiated Phase II Trial at MD Anderson Cancer Center combining CB-103 and Venetoclax for the treatment of rr/r-T-ALL patients is now open for recruitment...
31.01.2023
BioVersys AG announces first patient dosed in Phase 2a clinical trial with BVL-GSK099, to investigate a new treatment concept to address multidrug-resistance tuberculosis...
05.01.2023
BioVersys AG announces extension of its Series C investment round to CHF 32.6 million as the AMR Action Fund makes its first European-based investment...
26.10.2022
We are pleased to announce that Christian Harr (current COO) will become the new CEO of Tech Park Basel. He will take up the new position on...
23.09.2022
Impressive first edition: The Regio Basel 2022 Industry Night was also a great success at Tech Park Basel. 44 companies from Basel and the region opened their ...